Psilocybin therapy for depression faces unresolved FDA, reimbursement, training, and delivery risks even after COMPASS reports two positive phase 3 results

Psilocybin therapy for depression remains commercially and clinically uncertain even after COMPASS Pathways reported two positive phase 3 trial results and the FDA issued final guidance for psychedelic drug development. Regulatory progress does not remove the practical risks around approval standards, labeling, therapist involvement, site readiness, and payer acceptance. COMPASS Pathways sits at the center of the field because its late-stage program could shape how prescription psilocybin is evaluated and delivered in mainstream medicine. Key uncertainties include how much psychotherapy or support must accompany dosing, how clinics will staff and train facilitators, how safety monitoring will work at scale, and whether insurers will reimburse a time-intensive care model. Psilocybin's prospects therefore depend not only on efficacy data, but also on operational feasibility, business economics, and the willingness of regulators and health systems to absorb a novel treatment framework. The wider implication is that successful trials may be necessary for approval, yet still insufficient for broad adoption.